Andreas Argyrides
Stock Analyst at Chardan Capital
(4.32)
# 1,319
Out of 4,509 analysts
393
Total ratings
45.2%
Success rate
9.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Maintained: Buy | $10 → $13 | $3.81 | +241.21% | 2 | Jul 6, 2026 | |
| EYPT EyePoint | Maintained: Buy | $65 | $14.28 | +355.18% | 1 | Jul 1, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $4.06 | +97.04% | 20 | Jun 25, 2026 | |
| SVRA Savara | Maintained: Buy | $11 | $5.74 | +91.64% | 6 | Jun 3, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $40 | $23.64 | +69.20% | 9 | May 21, 2026 | |
| UTHR United Therapeutics | Rated: Hold | n/a | $535.57 | - | 19 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $3.73 | - | 8 | May 11, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $12.99 | - | 3 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $71.21 | - | 17 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $0.1441 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $103.33 | - | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.10 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.41 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.74 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.04 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $98 | $59.31 | +65.23% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $35.54 | +74.45% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $12.10 | +247.11% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.70 | +429.41% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $7 | $2.06 | +239.81% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $18.82 | +96.60% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $1.09 | +68,707.34% | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.6326 | - | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.02 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $13.50 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $75 | $0.249 | n/a | 18 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $105 | $21.30 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.073 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $13.15 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $12.75 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $25.54 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $59.20 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $14.64 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $265.22 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8178 | n/a | 6 | Aug 25, 2022 |
Opus Genetics
Jul 6, 2026
Maintained: Buy
Price Target: $10 → $13
Current: $3.81
Upside: +241.21%
EyePoint
Jul 1, 2026
Maintained: Buy
Price Target: $65
Current: $14.28
Upside: +355.18%
Aquestive Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $8
Current: $4.06
Upside: +97.04%
Savara
Jun 3, 2026
Maintained: Buy
Price Target: $11
Current: $5.74
Upside: +91.64%
Dyne Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $40
Current: $23.64
Upside: +69.20%
United Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $535.57
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.73
Upside: -
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $12.99
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $71.21
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $0.1441
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $103.33
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.10
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $20.41
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $7.74
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $4.04
Upside: -
Apr 24, 2026
Maintained: Buy
Price Target: $105 → $98
Current: $59.31
Upside: +65.23%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $35.54
Upside: +74.45%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $12.10
Upside: +247.11%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.70
Upside: +429.41%
Nov 11, 2025
Maintained: Buy
Price Target: $3 → $7
Current: $2.06
Upside: +239.81%
Oct 9, 2025
Maintained: Buy
Price Target: $37
Current: $18.82
Upside: +96.60%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $1.09
Upside: +68,707.34%
Jul 17, 2025
Rated: Hold
Price Target: n/a
Current: $0.6326
Upside: -
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.02
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $13.50
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $75
Current: $0.249
Upside: n/a
Aug 13, 2024
Maintained: Hold
Price Target: $105
Current: $21.30
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.073
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $13.15
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $12.75
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $25.54
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $59.20
Upside: n/a
Feb 22, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $14.64
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $265.22
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $0.8178
Upside: n/a